Mutación del gen BRAF en pacientes con cánceres de colon y recto con KRAS no mutado / BRAF gene mutation in wild-type KRAS patients with colorectal cancers
Rev. méd. Chile
;
142(1): 55-60, ene. 2014. ilus, tab
Article
in Spanish
| LILACS
| ID: lil-708851
ABSTRACT
Background:
In colorectal cancer, BRAF and KRAS mutation are mutually exclusive, but both are independent prognostic factors for the disease.Aim:
To determine the frequency of BRAF V600E mutation in colorectal cancer. Material andMethods:
A KRAS mutation study was carried out in 100 tissue samples of primary and metastatic adenocarcinomas of colon and rectum from patients aged 61.1 ± 62 years (56 women). Negative KRAS mutation cases underwent study of BRAF V600E mutation by restriction fragment length polymorphism (RFLP) and direct sequencing.Results:
Primary tumors were located in the colon and rectum in 88 and six cases respectively. Five were liver metastases and in one case, the sample location was undetermined. Forty two samples were KRAS positive (mutated). In 12 of the 58 KRAS negative (wild type) samples, the V600E mutation in codon 15 of the BRAF gene was demonstrated. No differences in the frequency and distribution of mutations, stratified by gender, age, primary tumor versus metastasis, or tumor location were observed.Conclusions:
Twelve percent of KRAS negative colorectal cancer samples showed BRAF gene mutation. Considering that 42% of samples have a KRAS mutation, 54% of patients should not respond to therapies with monoclonal antibodies directed against epidermic growth factor (EGFR) pathway.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Colorectal Neoplasms
/
Adenocarcinoma
/
Proto-Oncogene Proteins
/
Ras Proteins
/
Proto-Oncogene Proteins B-raf
/
Mutation
Type of study:
Prognostic study
Limits:
Female
/
Humans
/
Male
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2014
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Creative Bioscience/CL
Similar
MEDLINE
...
LILACS
LIS